Autoimmune Liver Disease: Diagnosis and Therapy;Autoimmune Lebererkrankungen: Diagnostik und Therapie

Zeitschrift fur Gastroenterologie

Volumn 42, Issue 1, 2004, Pages 19-30

  Bayer, E M ^a   Schramm, C ^a   Kanzler, S ^a   Lohse, Ansgar W ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Autoimmune hepatits; Immunosuppressive therapy; Liver transplantation; Overlap syndromes; Primary biliary cirrhosis; Primary sclerosing cholangitis

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TACROLIMUS; URSODEOXYCHOLIC ACID;

ANTIBODY BLOOD LEVEL; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE LIVER DISEASE; CUSHING SYNDROME; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; EUROPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MONOTHERAPY; NORTH AMERICA; OSTEOPOROSIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PROGNOSIS; REMISSION; REVIEW; STEROID THERAPY; SYNDROME DELINEATION; TREATMENT INDICATION; TREATMENT PLANNING;

ADULT; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AZATHIOPRINE; BIOPSY; CHILD; CHOLAGOGUES AND CHOLERETICS; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CHOLANGITIS, SCLEROSING; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOASSAY; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER CIRRHOSIS, BILIARY; LIVER DISEASES; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROGNOSIS; URSODEOXYCHOLIC ACID;

EID: 0345826139     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-812686     Document Type: Review

References (111)

1. Boberg KM, Aadland E, Jahnsen Jet et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998; 33: 99-103
2. Samuel D, Figueiro J, Bismuth H. Liver transplantation: Indications and patient selection. In: O'Grady J, Luke JR, Howdle PD (Hrsg). Comprehensive Clinical hepatology 2000; 34: 1-17
3. Milkiewicz P, Hubscher SG, Skiba G et al. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999; 68: 253-256
4. Wiesner RH, Demetris AJ, Belle SH et al. Acute allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998; 28: 638-645
5. Kanzler S, Galle PR, Meyer zum Büschenfelde KH et al. Long term management and prognosis of autoimmune hepatitis (AIH): a single centre experience. Z Gastroenterol 2001; 39: 339-348
6. Lohse AW, Gerken G, Mohr H et al. Relation between autoimmune liver diseases and viral hepatitis: Clinical and serological characteristics in 859 patients. Z Gastroenterol 1995; 33: 527-533
7. Czaja AJ, Doherty DG, Donaldson PT. Genetic bases of autoimmune hepatitis. Dig Dis Sci 2002; 47 (10): 2139-2150
8. Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group report: review of criteria for the diagnosis of autoimmune hepatitis. J Hepatol: Meeting report 1999, 1999; 31: 929-938
9. Heathcote EJ. Management of Primary Biliary Cirrhosis. Hepatology 2000; 31: 1005-1013
10. Lohse AW, Meyer zum Büschenfelde KH, Franz B et al. Characterisation of the "overlap syndrome" of primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) in genetically susceptible individuals. Hepatology 1999; 29: 1078-1084
11. Dienes HP, Gerken G, Lohse AW et al. Morphological aspects of overlap syndromes. In: Berg P, Lohse AW, Tiegs G, Wendel A (Hrsg). Autoimmune Liver Disease. Lancaster: Kluwer Academic Publishers, 1997: 80-85
12. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998: 28: 360-365
13. Fainboim L, Marcos Y, Pando M et al. Chronic active autoimmune hepatitis in children, Strong association with a particular HLA DR6 (DRB1*1301) haplotype. Hum Immunol 1994; 41: 146-150
14. Gregorio GV, Portmann B, Reid F et al. Autoimmune hepatitis in childhood. A 20 year survey. Hepatology 1997; 25: 541-547
15. Czaja AJ, Dos Santos RM, Porto A et al. Immune phenotype of chronic liver disease. Dig Dis Sci 1998; 43: 2149-2155
16. Schramm C, Kanzler S, zum Buschenfelde KH et al. Autoimmune hepatitis in the elderly. Am J Gastroenterol 2001; 96: 1587-1591
17. Gershwin ME, Mackay IR. Primary biliary cirrhosis: a paradigm or paradox for autoimmunity. Gastroenterology 1990; 99: 822-833
18. Ponsioen CI, Tytgat GN. Primary sclerosing cholangitis: a clinical review. Am J Gastroenterol 1998; 93: 515-523
19. Mang FW, Michieletti P, O'Rourke K et al. Primary biliary cirrhosis, sicca complex, and dysphagia. Dysphagia 1997; 12: 167-170
20. Bergasa NV, Alling DN, Talbot TL et al. Effects of naloxone infusions in patients with the pruritus of cholestasis: a double-blind, randomized, controlled trial. Ann Intern Med 1995; 123: 161-167
21. Porta G, Da Costa Gayotto LC, Alvarez F. Anti-liver-kidney microsome antibody-positive autoimmune hepatitis presenting as fulminant liver failure. J Ped Gastrenterol Nutrition 1990; 11: 138-140
22. Meyer zum Büschenfelde KH, Lohse AW. Autoimmune hepatitis (editorial). N Engl J Med 1995; 333: 1004-1005
23. Homberg JC, Abuaf N, Bernard O et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 1987; 7: 1333-1339
24. Czaja AJ, Manns MP. The validity and importance of subtypes of autoimmune hepatitis: a point of view. Am J Gastroenterol 1995; 90: 1206-1211
25. Stechemesser E, Klein R, Berg PA. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology 1993; 18: 1-9
26. Manns M, Gerken G, Kyriatsoulis A et al. Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987; 1: 292-294
27. Czaja AJ. Behavior and significance of autoantibodies in type I autoimmune hepatitis. J Hepatol 1999; 30: 394-401
28. Czaja AJ, Nishioka M, Morshed SA et al. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 1994; 107: 200-207
29. Czaja AJ, Homburger HA. Autoantibodies in liver disease. Gastroenterology 2001; 120: 239-249
30. Herkel J, Heidrich B, Nieraad N et al. Fine specificity of autoantibodies to soluble liver antigen and liver/pancreas. Hepatology 2002; 35: 403-408
31. Wies I, Brunner S, Henninger J et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000; 355: 1510-1515
32. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 2002: 97: 413-419
33. Dienes HP, Erberich H, Dries V et al. Autoimmune hepatitis and overlap syndromes. Clin Liver Dis 2002; 6: 349-362
34. Sherlock S, Scheuer PJ. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 1973; 289: 674-678
35. Doniach D, Roitt IM, Walker JG et al. Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications. Clin Exp Immunol 1966: 1: 237-262
36. Fussey S, Guest JR, James O et al. Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc Natl Acad Sci USA 1988; 85: 8654-8658
37. Kitami N, Komada T, Ishu H et al. Immunological study of anti-M2 in antimitochondrial antibody-negative primary biliary cirrhosis. Intern Med 1995; 34: 496-501
38. Mitchison HC, Bassendine MF, Hendrick A et al. Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? Hepatology 1986; 6: 1279-1284
39. Metcalf JV, Mitchison HC, Palmer JM et al. Natural history of early primary biliary cirrhosis. Lancet 1996; 348: 1399-1402
40. Ludwig J, Dickson ER, McDonald GSA. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch (A) 1978; 379: 103-112
41. Roll J, Boyer JL, Barry D et al. The prognostic importance of clinical and histological features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983: 308: 1-7
42. Sherlock S. The syndrome of disappearing intrahepatic bile ducts. Lancet 1987; 1: 493-496
43. Chazouilleres O, Wendum D, Serfaty L et al. Primary biliary cirrhosisautoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28: 296-301
44. Boberg KM, Lundin KE, Schrumpf E. Etiology and pathogenesis in primary sclerosing cholangitis. Scand J Gastroenterol Suppl 1994; 204: 47-58
45. Wiesner RH, LaRusso NF. Clinicopathogenic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980; 79: 200-206
46. Chapman RWG, Marborgh BA, Rhodes JM et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980; 21: 870-877
47. Schrumpf E, Elgjo K, Fausa O et al. Sclerosing cholangitis in ulcerative colitis. Scand J Gastrenterol 1980; 15: 689-697
48. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 2002; 51: 562-566
49. Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology 2002; 35: 1494-1500
50. Hubscher SG. Histological classification of autoimmune cholestatic liver diseases. In: Manns MP, Paumgartner G, Leuschner U (Hrsg). Kluwer Academic Publishers. Dordrecht: Immunology and Liver, 2000: 223-243
51. Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology 1999; 30: 325-332
52. Helmreich-Becker I, Schirmacher P, Denzer U et al. Minilaparoscopy in the diagnosis of cirrhosis: superiority in patients with Child-Pugh A and macronodular disease. Endoscopy 2003; 35: 55-60
53. Bergquist A, Broome U. Hepatobiliary and extra-hepatic malignancies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001; 15: 643-656
54. Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology 2003; 37: 961-969
55. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998; 28: 360-365
56. Lohse AW, Meyer zum Büschenfelde KH, Franz B et al. Characterisation of the "overlap syndrome" of primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) in genetically susceptible individuals. Hepatology 1999; 29: 1078-1084
57. Gohlke F, Lohse AW, Dienes HP et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol 1996; 24: 699-705
58. Minuk GY, Sutherland LR, Pappas SC et al. Autoimmune chronic active hepatitis (lupoid hepatitis) and primary sclerosing cholangitis in two young adult females. Can J Gastroenterol 1988; 2: 22-27
59. Boberg KM, Fausa O, Haaland T et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996; 23: 1369-1376
60. Luketic VA, Gomez DA, Sanyal AJ et al. An atypical presentation for primary sclerosing cholangitis. Dig Dis Sci 1997; 42: 2009-2016
61. Geubel AP, Baggenstoss AH, Summerskill WHJ. Responses to treatment can differentiate chronic active liver disease with cholangitic features from the primary biliary cirrhosis syndrome. Gastroenterology 1976; 71: 444-449
62. Forbes A, Blanchard C, Gazzard B. Natural history of AIDS-related sclerosing cholangitis: a study of 20 cases. Gut 1993; 34: 116-121
63. Devaney K, Goodman ZD, Epstein MS et al. Hepatic sarcoidosis. Clinico-pathologic features in 100 patients. Am J Surg Pathol 1993; 17: 1272-1280
64. Ilan Y, Rappaport I, Feigin R et al. Primary sclerosing cholangitis in sarcoidosis. J Clin Gastroenterol 1993; 16: 326-328
65. Romero-Gomez M, Suarez-Garcia E, Otero MA et al. Sarcoidosis, sclerosing cholangitis, and chronic atrophic autoimmune gastritis: a case of infiltrative sclerosing cholangitis. J Clin Gastroenterol 1998; 27: 162-165
66. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 159-185
67. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1: 735-737
68. Soloway RD, Summerskill WH, Baggenstoss AH et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820-833
69. Summerskill WHJ, Korman MG, Ammon HV et al. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975; 16: 876-883
70. Kanzler S, Galle PR, Meyer zum Büschenfelde KH et al. Long term management and prognosis of autoimmune hepatitis (AIH): a single centre experience. Z Gastroenterol 2001; 39: 339-348
71. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995; 12: 958-963
72. Meyer zum Büschenfelde KH, Lohse AW. Autoimmune hepatitis (editorial) N Engl J Med 1995; 333: 1004-1005
73. Bayer EM, Herr W, Kanzler S et al. Transforming growth factor-β1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity. J Hepatology 1998; 28: 803-811
74. Kanzler S, Gerken G, Löhr H et al. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001; 34: 354-355
75. Summerskill WHJ, Korman MG, Ammon HV et al. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975; 16: 876-883
76. Kanzler S, Gerken G, Dienes HP et al. Cyclophosphamide as an alternative immunosuppressive therapy for autoimmune hepatitis - report of three cases. Z Gastroenterol 1997; 35: 571-578
77. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000; 33: 371-375
78. Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998; 29: 990-993
79. Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type 1 autoimmune chronic active hepatitis. J Hepatol 1994; 21: 1040-1047
80. Person JL, McHutchison JG, Fong TL et al. A case of cyclosporine-sensitive, steroid-resistant, autoimmune chronic active hepatitis. J Clin Gastroenterol 1993; 17: 317-320
81. Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995; 36: 459-461
82. Hyams JS, Ballow M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 1987; 93: 890-893
83. Medina J, García-Buey L, Moreno-Otero R. Immunopathogenetic and therapeutic aspects of autoimmune hepatitis. Alimentary Aliment Pharmacol Ther 2003; 17 (1): 1-16
84. Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000; 119: 1312-1316
85. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994; 8: 585-590
86. Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med 1994; 330: 1342-1347
87. Heathcote EJ, Cauch-Dudek K, Walker V et al. The Canadian multicentre double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19: 1149-1156
88. Lindor KD, Dickson ER, Baldus WP et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 1284-1290
89. Combes B, Carithers RL, Maddrey WC et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22: 759-766
90. Ludwig J, Dickson ER, McDonald GSA. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch (A) 1978; 379: 103-112
91. Poupon RE, Lindor KD, Pares A et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003; 39: 12-16
92. Leuschner M, Maier KP, Schlichting J et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999; 117: 918-925
93. Newton J, Jones D. Osteoporosis in primary biliary cirrhosis. Panminerva Med 2002; 44: 335-341
94. Newton J, Francis R, Prince M et al. Osteoporosis in primary biliary cirrhosis revisited. Gut 2001; 49: 282-287
95. Lindor KD, the Mayo Primary Sclerosing Cholangitis-UDCA Study Group. Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997; 336: 691-695
96. Mitchell SA, Bansi DS, Hunt N et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001; 121: 900-907
97. Harnois DM, Angulo P, Jorgensen RA et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001; 96: 1558-1562
98. Tung BY, Emond MJ, Haggitt RC et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 16: 89-95
99. Pardi DS, Loftus EV Jr, Kremers WK et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889-893
100. Skolkin MD, Alspaugh JP, Casarella WJ et al. Sclerosing cholangitis: palliation with percutaneous cholangioplasty. Radiology 1989; 170: 199-206
101. Mueller PR, van Sonnenberg E, Ferrucci JT Jr et al. Biliary stricture dilatation: multicenter review of clinical management in 73 patients. Radiology 1986; 160: 17-22
102. Johnson GK, Geenen JE, Venu RP et al. Endoscopic treatment of biliary tract strictures in sclerosing cholangitis: a larger series and recommendations for treatment. Gastrointest Endosc 1991; 37: 38-43
103. Lombard M, Farrant M, Karani J et al. Improving biliary-enteric drainage in primary sclerosing cholangitis: experience with endoscopic methods. Gut 1991; 32: 1364-1368
104. Gaing AA, Geders JM, Cohen SA et al. Endoscopic management of primary sclerosing cholangitis: review, and report of an open series. Am J Gastroenterol 1993; 88: 2000-2008
105. Rosen CB, Nagorney DM. Cholangiocarcinoma complicating primary sclerosing cholangitis. Semin Liver Dis 1991; 11: 26-30
106. Schrumpf E, Abdelnoor M, Fausa O et al. Risk factors in primary sclerosing cholangitis. J Hepatol 1994; 21: 1061-1066
107. Schramm C, Helmreich-Becker I, Schirmacher P et al. Combined immunosuppressive therapy with azathioprine and prednisolone in primary sclerosing cholangitis Ann. Intern Med 1999; 131: 943-946
108. Marsh JW Jr, lwatsuki S, Makowka L et al. Orthotopic liver transplantation for primary sclerosing cholangitis. Ann Surg 1988; 207: 21-25
109. Broome U, Eriksson LS. Assessment for liver transplantation in patients with primary sclerosing cholangitis. J Hepatol 1994; 20: 654-659
110. May GR, Bender CE, LaRusso NF et al. Nonoperative dilatation of dominant strictures in primary sclerosing cholangitis. AJR Am J Roentgenol 1985; 145: 1061-1064
111. Poupon RE, Lindor KD, Cauch-Dudek K et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884-890